24/7 Market News Snapshot 28 July, 2025 – AIM ImmunoTech Inc. (NYSE:AIM)

July 28, 2025

DENVER, Colo., 28 July, 2025 (www.247marketnews.com) – (NYSE:AIM) are discussed in this article.
AIM ImmunoTech Inc. has been making headlines recently, marked by significant developments in both market activity and clinical research. Following an unprecedented volatility in its stock, AIM began trading today with a notable opening price of $18.98, only to witness a dramatic decline, currently trading at $14.855—representing a staggering drop of 76.85%. This substantial fluctuation has attracted increased trading volume, which has surged to 1.86 million shares, reflecting heightened investor interest in AIM’s promising therapeutic endeavors. Such market movements can present intriguing opportunities for investors as AIM navigates through this turbulent session.

Adding to the company’s notable presence is the recent mid-year update from its Phase 2 DURIPANC study, examining the combined effects of Ampligen® (rintatolimod) and AstraZeneca’s durvalumab in treating metastatic pancreatic cancer. The study, overseen by Prof. Casper van Eijck at Erasmus Medical Center, is pivotal for patients who have shown stable disease after FOLFIRINOX treatment. Current findings reveal that 14 of the targeted 25 subjects have been enrolled, with encouraging preliminary results showcasing the combination therapy’s tolerability and potential efficacy.

Notably, approximately 21% of patients are experiencing progression-free survival beyond six months, and a striking 64% are surpassing the six-month overall survival mark, offering a glimmer of hope in a notoriously challenging treatment landscape. AIM’s CEO, Thomas K. Equels, underscored the importance of these findings, suggesting a clear trajectory for integrating Ampligen’s immune modulation with immune checkpoint inhibition through durvalumab. As AIM pursues further analysis into these promising results, the commitment to advancing treatment options for pancreatic cancer remains firmly in focus, aiming to enhance patient outcomes and foster new avenues of hope against this aggressive disease.

Related news for (AIM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.